TY - JOUR
T1 - Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE
AU - Husser, Oliver
AU - Núñez, Julio
AU - Burgdorf, Christof
AU - Holzamer, Andreas
AU - Templin, Christian
AU - Kessler, Thorsten
AU - Bodi, Vicente
AU - Sanchis, Juan
AU - Pellegrini, Costanza
AU - Luchner, Andreas
AU - Maier, Lars S.
AU - Schmid, Christof
AU - Lüscher, Thomas F.
AU - Schunkert, Heribert
AU - Kastrati, Adnan
AU - Hilker, Michael
AU - Hengstenberg, Christian
N1 - Publisher Copyright:
© 2016 Sociedad Española de Cardiología
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Introduction and objectives Conventional risk scores have not been accurate in predicting peri- and postprocedural risk of patients undergoing transcatheter aortic valve implantation (TAVI). Elevated levels of the tumor marker carbohydrate antigen 125 (CA125) have been linked to adverse outcomes after TAVI. We studied the additional value of CA125 to that of the EuroSCORE in predicting long-term mortality after TAVI. Methods and results During a median follow-up of 59 weeks, 115 of 422 patients (27%) died after TAVI. Mortality was higher with elevated CA125 (> 30 U/mL) and EuroSCORE (> median) (47% vs 20%, P < .001 and 38% vs 16%, P < .001, respectively). In the multivariable analysis, CA125 (> 30 U/mL) remained an independent predictor of mortality (hazard ratio [HR], 2.16; 95% confidence interval [95%CI], 1.48-3.15; P < .001) and improved the predictive capability of the model (C-statistic: 0.736 vs 0.731) and the net reclassification index (51% 95%CI, 33-73) with an integrated discriminative improvement of 3.5% (95%CI, 0.5-8.4). A new variable (CA125-EuroSCORE) was created, with the combinations of the 2 possible binary states of these variables (+, elevated, -, not elevated; C1: CA125- EuroSCORE-; C2: CA125+ EuroSCORE-; C3: CA125- EuroSCORE+; C4: CA125+ EuroSCORE+). Patients in C1 exhibited the lowest cumulative mortality rate (14% [26 of 181]). Mortality was intermediate for C2 (CA125 > 30 U/mL and EuroSCORE ≤ median) and C3 (CA125 ≤ 30 U/mL and EuroSCORE > median): 27% (8 of 30) and 28% (37 of 131), respectively. Patients in C4 (CA125 > 30 U/mL and EuroSCORE > median) exhibited the highest mortality (55% [44 of 80], P-value for trend < .001). Conclusions CA125 offers additional prognostic information beyond that obtained by the EuroSCORE. Elevation of both markers was associated with a poor prognosis. Full English text available from: www.revespcardiol.org/en
AB - Introduction and objectives Conventional risk scores have not been accurate in predicting peri- and postprocedural risk of patients undergoing transcatheter aortic valve implantation (TAVI). Elevated levels of the tumor marker carbohydrate antigen 125 (CA125) have been linked to adverse outcomes after TAVI. We studied the additional value of CA125 to that of the EuroSCORE in predicting long-term mortality after TAVI. Methods and results During a median follow-up of 59 weeks, 115 of 422 patients (27%) died after TAVI. Mortality was higher with elevated CA125 (> 30 U/mL) and EuroSCORE (> median) (47% vs 20%, P < .001 and 38% vs 16%, P < .001, respectively). In the multivariable analysis, CA125 (> 30 U/mL) remained an independent predictor of mortality (hazard ratio [HR], 2.16; 95% confidence interval [95%CI], 1.48-3.15; P < .001) and improved the predictive capability of the model (C-statistic: 0.736 vs 0.731) and the net reclassification index (51% 95%CI, 33-73) with an integrated discriminative improvement of 3.5% (95%CI, 0.5-8.4). A new variable (CA125-EuroSCORE) was created, with the combinations of the 2 possible binary states of these variables (+, elevated, -, not elevated; C1: CA125- EuroSCORE-; C2: CA125+ EuroSCORE-; C3: CA125- EuroSCORE+; C4: CA125+ EuroSCORE+). Patients in C1 exhibited the lowest cumulative mortality rate (14% [26 of 181]). Mortality was intermediate for C2 (CA125 > 30 U/mL and EuroSCORE ≤ median) and C3 (CA125 ≤ 30 U/mL and EuroSCORE > median): 27% (8 of 30) and 28% (37 of 131), respectively. Patients in C4 (CA125 > 30 U/mL and EuroSCORE > median) exhibited the highest mortality (55% [44 of 80], P-value for trend < .001). Conclusions CA125 offers additional prognostic information beyond that obtained by the EuroSCORE. Elevation of both markers was associated with a poor prognosis. Full English text available from: www.revespcardiol.org/en
KW - Logistic EuroSCORE
KW - Risk prediction
KW - Transcatheter aortic valve implantation
KW - Tumor marker carbohydrate antigen 125
UR - http://www.scopus.com/inward/record.url?scp=85005925770&partnerID=8YFLogxK
U2 - 10.1016/j.recesp.2016.07.027
DO - 10.1016/j.recesp.2016.07.027
M3 - Article
C2 - 27623490
AN - SCOPUS:85005925770
SN - 0300-8932
VL - 70
SP - 186
EP - 193
JO - Revista Espanola de Cardiologia
JF - Revista Espanola de Cardiologia
IS - 3
ER -